Leanne Peiser
About Leanne Peiser
Leanne Peiser is the Executive Director of Immune Oncology and Cellular Therapy Translational Research at Bristol Myers Squibb, with extensive experience in immuno-oncology and cellular therapy translational development.
Company
Leanne Peiser is currently employed at Bristol Myers Squibb, serving as the Executive Director for Immune Oncology and Cellular Therapy Translational Research. She has been with the company in various capacities since 2019, reflecting her continued commitment to advancing translational research in immune oncology and cellular therapy.
Title
Leanne Peiser holds the position of Executive Director, Immune Oncology and Cellular Therapy Translational Research at Bristol Myers Squibb. She leads a group of six translational scientists, focusing on cutting-edge research in the field.
Education and Expertise
Leanne Peiser earned her PhD in Immunology from the University of Oxford from 1996 to 2001. She also holds a B.Sc (MED)(HONS) in Medical Biochemistry and a B.Sc. in Microbiology and Biochemistry from the University of Cape Town. Her extensive education provides a robust foundation for her work in immune oncology and cellular therapy.
Background
Prior to her current role at Bristol Myers Squibb, Leanne Peiser amassed significant experience in various positions. She was a Senior Director and Director in the same field at Bristol Myers Squibb, following similar roles at Celgene, FLX Bio, Gilead Sciences, and Amgen. Her extensive background includes cross-functional scientific support, biomarker development, and target screening.
Achievements
Leanne Peiser has led critical projects, such as filing an Investigational New Drug (IND) application for HBV immunotherapy at Gilead in 2016. She has also developed novel resources for biomarker development and has been recognized as an expert on macrophage host:pathogen interactions. Her contributions span multiple companies and research areas, cementing her as a leader in her field.